Malignancies
15
1
3
9
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
6.7%
1 terminated out of 15 trials
90.0%
+3.5% vs benchmark
7%
1 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (15)
Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma
Identifying Tissue-of-origin in Transplant Patients and Patients with Malignancies.
9-ING-41 in Patients with Advanced Cancers
Cancer Therapy-related Cardiac Dysfunction Occuring in Children Treated by Anticancer Drugs for Malignancies
Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143
Longitudinal Evaluation Study of Vaginal Stenosis With and Without Pelvic Radiation Therapy
Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors
Study of PWT33597 Mesylate in Subjects With Advanced Malignancies
Study of Satraplatin With Capecitabine to Treat Advanced Solid Malignancies
Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell Lymphoma
Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)